| Joy M Samanich, MD | |
|
1 Hunter Ave Ste A, Armonk, NY 10504-2025 | |
| (914) 236-0336 | |
| (914) 940-0330 |
| Full Name | Joy M Samanich |
|---|---|
| Gender | Female |
| Speciality | Medical Genetics - Clinical Genetics (m.d.) |
| Location | 1 Hunter Ave Ste A, Armonk, New York |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1285710137 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | 235588 (New York) | Secondary |
| 207SG0201X | Medical Genetics - Clinical Genetics (m.d.) | 235588 (New York) | Primary |
| Entity Name | Montefiore Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063525152 PECOS PAC ID: 3779496021 Enrollment ID: O20031113000235 |
News Archive
Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces the availability of their proprietary FATZO model in a European based laboratory.
A performance evaluation process used widely by Fortune 500 companies accurately and effectively assesses surgeons' adherence to core standards of excellence and spurs changes in behavior to improve surgical practice and teamwork, according to a new study published online as an "article in press" in the Journal of the American College of Surgeons.
Fatal overdoses involving stimulants (cocaine and other psychostimulants, primarily methamphetamine) have been increasing over the past few years.
Students preparing for final exams might want to wait before pulling an all-night cram session - at least as far as their neurons are concerned. Carnegie Mellon University neuroscientists have discovered a new intermediate phase in neuronal development during which repeated exposure to a stimulus shrinks synapses.
Cytokine-activated natural killer (NK) cells derived from donated umbilical cord blood, combined with an investigational bispecific antibody targeting CD16a and CD30 known as AFM13, displayed potent anti-tumor activity against CD30+ lymphoma cells, according to a new preclinical study from researchers at The University of Texas MD Anderson Cancer Center.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Joy M Samanich, MD 1 Hunter Ave Ste A, Armonk, NY 10504-2025 Ph: (914) 236-0336 | Joy M Samanich, MD 1 Hunter Ave Ste A, Armonk, NY 10504-2025 Ph: (914) 236-0336 |
News Archive
Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces the availability of their proprietary FATZO model in a European based laboratory.
A performance evaluation process used widely by Fortune 500 companies accurately and effectively assesses surgeons' adherence to core standards of excellence and spurs changes in behavior to improve surgical practice and teamwork, according to a new study published online as an "article in press" in the Journal of the American College of Surgeons.
Fatal overdoses involving stimulants (cocaine and other psychostimulants, primarily methamphetamine) have been increasing over the past few years.
Students preparing for final exams might want to wait before pulling an all-night cram session - at least as far as their neurons are concerned. Carnegie Mellon University neuroscientists have discovered a new intermediate phase in neuronal development during which repeated exposure to a stimulus shrinks synapses.
Cytokine-activated natural killer (NK) cells derived from donated umbilical cord blood, combined with an investigational bispecific antibody targeting CD16a and CD30 known as AFM13, displayed potent anti-tumor activity against CD30+ lymphoma cells, according to a new preclinical study from researchers at The University of Texas MD Anderson Cancer Center.
› Verified 8 days ago